Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44)
The summary for the Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44): The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the SBIR program. SBIR Phase I projects under this FOA supportpreliminary steps in the process for lead optimization or preclinical development of therapeutics. SBIR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a SBIR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.
Federal Grant Title: | Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-17-130 |
Type of Funding: | Grant |
CFDA Numbers: | 93.847 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | January 5th, 2020 |
Original Application Deadline: | January 5th, 2020 |
Posted Date: | January 24th, 2017 |
Creation Date: | January 24th, 2017 |
Archive Date: | February 5th, 2020 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | January 24th, 2017 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PA-17-130.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
- • Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
- • Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors...
- • NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Requ...
- • NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...
- • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
- • Molecular Therapy Core Centers
- • Pilot and Feasibility Program in Human Islet Biology
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)